Literature DB >> 17999181

Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein.

Wai Haung Yu1, Yasuji Matsuoka, István Sziráki, Audrey Hashim, John Lafrancois, Henry Sershen, Karen E Duff.   

Abstract

Familial Parkinson's disease (PD) has been linked to point mutations and duplication of the alpha-synuclein gene and mutant alpha-synuclein expression increases the vulnerability of neurons to exogenous insults. In this study, we analyzed the levels of dopamine and its metabolites in the olfactory bulb (OB), and nigrostriatal regions of transgenic mice expressing human, mutant A53T alpha-synuclein (alpha-syn tg) and their non-transgenic (ntg) littermates using a sub-toxic, moderate dose of MPTP to determine if mutant human alpha-synuclein sensitizes the central dopaminergic systems to oxidative stress. We observed that after a single, sub-lethal MPTP injection, dopamine levels were reduced in striatum and SN in both the alpha-syn tg and ntg mice. In the olfactory bulb, a region usually resistant to MPTP toxicity, levels were reduced only in the alpha-syn tg mice. In addition, we identified a significant increase in dopamine metabolism in the alpha-syn transgenic, but not ntg mice. Finally, MPTP treatment of alpha-syn tg mice was associated with a marked elevation in the oxidative product, 3-nitrotyrosine that co-migrated with alpha-synuclein. Cumulatively, the data support the hypothesis that mutant alpha-synuclein sensitizes dopaminergic neurons to neurotoxic insults and is associated with greater oxidative stress. The alpha-syn tg line is therefore useful to study the genetic and environmental inter-relationship in PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17999181     DOI: 10.1007/s11064-007-9533-4

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  72 in total

1.  Olfactory loss may be a first sign of idiopathic Parkinson's disease.

Authors:  Antje Haehner; Thomas Hummel; Cornelia Hummel; Ulrike Sommer; Susann Junghanns; Heinz Reichmann
Journal:  Mov Disord       Date:  2007-04-30       Impact factor: 10.338

2.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.

Authors:  Francesco Fornai; Oliver M Schlüter; Paola Lenzi; Marco Gesi; Riccardo Ruffoli; Michela Ferrucci; Gloria Lazzeri; Carla L Busceti; Fabrizio Pontarelli; Giuseppe Battaglia; Antonio Pellegrini; Ferdinando Nicoletti; Stefano Ruggieri; Antonio Paparelli; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

3.  The parkinsonian toxin MPTP: action and mechanism.

Authors:  Serge Przedborski; Vernice Jackson-Lewis; Ruth Djaldetti; Gabriel Liberatore; Miquel Vila; Slobodanka Vukosavic; Gabrielle Almer
Journal:  Restor Neurol Neurosci       Date:  2000       Impact factor: 2.406

4.  Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

Authors:  S Przedborski; Q Chen; M Vila; B I Giasson; R Djaldatti; S Vukosavic; J M Souza; V Jackson-Lewis; V M Lee; H Ischiropoulos
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

5.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Anthony Adame; Michael Alford; Leslie Crews; Makoto Hashimoto; Peter Seubert; Michael Lee; Jason Goldstein; Tamie Chilcote; Dora Games; Dale Schenk
Journal:  Neuron       Date:  2005-06-16       Impact factor: 17.173

6.  Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation.

Authors:  S Kanda; J F Bishop; M A Eglitis; Y Yang; M M Mouradian
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

7.  Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease.

Authors:  M Neystat; T Lynch; S Przedborski; N Kholodilov; M Rzhetskaya; R E Burke
Journal:  Mov Disord       Date:  1999-05       Impact factor: 10.338

8.  Characterization of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) binding sites in C57BL/6 mouse brain: mutual effects of monoamine oxidase inhibitors and sigma ligands on MPTP and sigma binding sites.

Authors:  Y Itzhak; D Mash; S H Zhang; I Stein
Journal:  Mol Pharmacol       Date:  1991-03       Impact factor: 4.436

9.  Effect of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on age-related changes in dopamine turnover and transporter function in the mouse striatum.

Authors:  H Sershen; M F Mason; A Hashim; A Lajtha
Journal:  Eur J Pharmacol       Date:  1985-07-11       Impact factor: 4.432

10.  Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.

Authors:  Zhizhong Dong; Boris Ferger; Joram Feldon; Hansruedi Büeler
Journal:  J Neurobiol       Date:  2002-10
View more
  16 in total

1.  α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment.

Authors:  Sonia George; Su San Mok; Milawaty Nurjono; Scott Ayton; David I Finkelstein; Colin L Masters; Qiao-Xin Li; Janetta G Culvenor
Journal:  J Mol Neurosci       Date:  2010-05-13       Impact factor: 3.444

Review 2.  Mitochondrial dysfunction in genetic animal models of Parkinson's disease.

Authors:  Alzbeta Trancikova; Elpida Tsika; Darren J Moore
Journal:  Antioxid Redox Signal       Date:  2011-10-04       Impact factor: 8.401

3.  Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease.

Authors:  Lonnie Schneider; Jianhua Zhang
Journal:  Mol Neurodegener       Date:  2010-04-13       Impact factor: 14.195

4.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

5.  Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis.

Authors:  Diogo Martins Branco; Daniela M Arduino; A Raquel Esteves; Diana F F Silva; Sandra M Cardoso; Catarina Resende Oliveira
Journal:  Front Aging Neurosci       Date:  2010-05-21       Impact factor: 5.750

6.  Genome-wide microarray analysis of the differential neuroprotective effects of antioxidants in neuroblastoma cells overexpressing the familial Parkinson's disease alpha-synuclein A53T mutation.

Authors:  Lei Ma; Tracy T Cao; Geeta Kandpal; Lee Warren; J Fred Hess; Guy R Seabrook; William J Ray
Journal:  Neurochem Res       Date:  2009-08-02       Impact factor: 3.996

Review 7.  α-Synuclein and nonhuman primate models of Parkinson's disease.

Authors:  Scott C Vermilyea; Marina E Emborg
Journal:  J Neurosci Methods       Date:  2015-08-03       Impact factor: 2.390

8.  Molecular and neurochemical mechanisms in PD pathogenesis.

Authors:  Irmgard Paris; Jorge Lozano; Carolina Perez-Pastene; Patricia Muñoz; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2009-05-20       Impact factor: 3.911

Review 9.  Mitochondrial CHCHD2: Disease-Associated Mutations, Physiological Functions, and Current Animal Models.

Authors:  Teresa R Kee; Pamela Espinoza Gonzalez; Jessica L Wehinger; Mohammed Zaheen Bukhari; Aizara Ermekbaeva; Apoorva Sista; Peter Kotsiviras; Tian Liu; David E Kang; Jung-A A Woo
Journal:  Front Aging Neurosci       Date:  2021-04-22       Impact factor: 5.750

10.  Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle.

Authors:  Kristen A Malkus; Elpida Tsika; Harry Ischiropoulos
Journal:  Mol Neurodegener       Date:  2009-06-05       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.